Case Report

The Outcome of Percutaneous Mitral Balloon Commissurotomy (PMBC) in Pregnant Women with Mitral Stenosis: An Evidence-Based Study

Luaran Komisurotomi Balon Mitral Perkutan pada Perempuan Hamil dengan Stenosis Mitral: Studi berbasis Bukti

Suskan Djusad, Sura Hamim, Raymond Suya, Hans Ransah, Ali Sungkar

Department of Obstetrics and Gynecology
Faculty of Medicine Universitas Indonesia
Dr. Cipto Mangunkusumo General Hospital
Jakarta

Abstract

Objective: To review the outcome of percutaneous mitral balloon commissurotomy (PMBC) both to maternal and neonatal survival.

Methods: The search was conducted on Pubmed®, Cochrane Library®, and Ovid® using MeSH. Critical appraisal determining the validity, importance, and applicability (VIA) was conducted by two independent authors. Pregnant women with MS with functional class grading based on NYHA

Results: Several studies showed that performing the PMBC had good outcome for pregnant women functional class based on NYHA. Most of them decreased from NYHA III/IV to I/II. For delivery outcome, all studies concluded that more than 80% pregnant women with mitral stenosis undergoing PMBC delivered at term, and no congenital anomalies found.

Conclusions: A decrease in NYHA functional class was observed after PMBC Percutaneous mitral balloon commissurotomy for pregnant women with severe MS is safe during pregnancy.

Keywords: mitral stenosis, outcome, percutaneous mitral balloon commissurotomy, pregnancy.

INTRODUCTION

Normal pregnancy is associated with adaptational circulatory state including 40-50% increase in cardiac output and decrease in systemic vascular resistance. The most common valvular heart lesion in child-bearing age women is Mitral Stenosis (MS). It is associated with significant maternal and fetal morbidity and mortality. MS in pregnancy will cause an increase in the transmural gradient with raised pressure in the pulmonary circulation. Thus, worsening signs of dyspnea, increase the risk of pulmonary edema and afib atrial fibrillation leading to thromboembolic event. Additionally, there is also significant risk for fetal complications such as premature birth and intrauterine growth restriction.

The management of severe MS can be divided into conservative, medical and surgical. All women with MS should reduce their activity and obtain β-blockers, diuretics, and anticoagulants. This regimen can reduce the New York Heart Association functional class III/IV to I/II.

Meanwhile, surgical management is indicated for patients with failure of aggressive medical therapy. Surgical commissurotomy as a choice...
is relatively safe with maternal mortality rate of ≤2%, fetal mortality rate of 1.2% to 8% for closed commissurotomy.

Meanwhile, open valvotomy and extracorporeal cardiopulmonary bypass has fetal mortality rate of 15-33%. Percutaneous mitral balloon commissurotomy (PMBC) has become an effective alternative to surgical commissurotomy. However, the result of this intervention is still limited. Therefore, this study aims to review the outcome of PMBC both to maternal and neonatal survivability.

CASE

A 35-year-old woman, G4P3 with 39 weeks of gestational age came to hospital in labour. When 4 months of pregnancy, she complained continuously shortness of breath, dyspnoea on exertion (DOE), orthopnoea (OP), paroxysmal nocturnal dyspnoea (PND). There was also cough every day without fever. On physical examination, there was diastolic murmur on mitral valve and rales on both lungs. Complete blood count showed within normal limit. Electrocardiography revealed atrial fibrillation normal rapid response. Echocardiography showed left atrial dilatation, normal right atrium and ventricle, MS severe (mean PG 8, planimetry MVA 0.61, Wilkins score 10, MR mild, TR moderate, good systolic LV function (EF 73%), hard to determine the diastolic LV function, good systolic RV function (TAPSE 20). She was diagnosed with mitral valve stenosis and undergoing PMBC. The procedure was performed on 19-20 weeks of gestational age by inserting the Inoue Balloon 24-26 mm through mitral valve to LV and running the PMBC 2 times. After procedure, the pressure gradient was around 7-8 mmHg. The clinical question is how does PMBC affect the survivability of pregnant women with MS?

METHODS

To answer the clinical question, the search was conducted on Pubmed®, Cochrane Library®, and Ovid®. In PubMed, the search included keywords using the MeSH, namely "Mitral Valve Stenosis" AND "Pregnancy" AND percutaneous mitral commissurotomy. Meanwhile, in Cochrane, the MeSH descriptor consisted of [Mitral Valve Stenosis] AND [Pregnancy] AND percutaneous mitral commissurotomy. The author used keywords of Mitral stenosis and Pregnancy and percutaneous mitral commissurotomy in Ovid. Of the searching strategy above performed in June 15th, 2018, there were 17, 0, and 26 studies in Pubmed®, Cochrane Library®, and Ovid® database, respectively. The articles were screened using the criteria consisting of abstracts answering the clinical question, written in English language, full-text paper availability, and omitting all duplication papers. After screening, there were 5 articles in appropriate to the inclusion criteria. Critical appraisal determining the validity, importance, and applicability (VIA) was conducted by 2 independent authors. The critical appraisal steps used in this article (figure 1)5,6

RESULTS

Of 5 studies appraised, all studies in appropriate with VIA criteria based on critical appraisal of prognostic study by Centre for Evidence-Based Medicine, University of Oxford, 2010. One study was considered less valid due to unclear baseline characteristics of samples. Besides, the samples underwent the PMBC was unclear. Other studies used the study samples as severe mitral stenosis not responding to standard medical therapy. Due to limited cases of severe MS in pregnancy, all studies did not run blind fashion for measuring the outcome and precision of the prognostic. Each study described the results by number of patients. Table 1 showed the result of appraisal prognostic studies.
The Outcome of Percutaneous 68

...atrial fibrillation (AF), and stroke. Pressure will raise the risk of thrombus formation, in pregnancy in relation to increase in left atrial period. The physiological of hypercoagulability will continue during and immediate postpartum oedema in 30 weeks of gestational age. This risk MR cases will experience episode of pulmonary than 1 cm. Around 60% of moderate to severe 2-2.5 cm with severe MS occurs in valve area less area by 2D echocardiography short axis. Patient usually complains after the valve area less than 1 cm. Around 60% of moderate to severe MR cases will experience episode of pulmonary oedema in 30 weeks of gestational age. This risk will continue during and immediate postpartum period. The physiological of hypercoagulability in pregnancy in relation to increase in left atrial pressure will raise the risk of thrombus formation, atrial fibrillation (AF), and stroke.

Table 1. Result of VIA on each Prognostic Study

<table>
<thead>
<tr>
<th>Study</th>
<th>Validity</th>
<th>Outcome in a blind fashion</th>
<th>Adjustment for important prognostic factors</th>
<th>Results</th>
<th>Precision of the prognostic</th>
<th>Similarity of patients</th>
<th>Clinically important impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sananes, et al.</td>
<td>Yes (severe mitral valve stenosis refractory to optimal medical therapy)</td>
<td>Not clear</td>
<td>No</td>
<td>N/A</td>
<td>Delivery outcome</td>
<td>9 patients delivered at term wga</td>
<td>Yes</td>
</tr>
<tr>
<td>Kalra, et al.</td>
<td>Yes (NYHA class IV and not responding to standard medical therapy of CHF)</td>
<td>Yes (monthly clinical and echocardiographic assessment and follow up 3 monthly intervals after that)</td>
<td>No</td>
<td>N/A</td>
<td>NYHA outcome</td>
<td>All patients are in NYHA class I and no evidence of restenosis</td>
<td>Yes</td>
</tr>
<tr>
<td>Fath, et al.</td>
<td>No</td>
<td>Yes (24 hours before and after balloon mitral commissurotomy, and four to six-month interval)</td>
<td>No</td>
<td>N/A</td>
<td>Delivery outcome</td>
<td>24 patients delivered at term</td>
<td>N/A</td>
</tr>
<tr>
<td>Abouzied, et al.</td>
<td>Yes (NYHA class II and IV, not controlled with conventional medical treatment)</td>
<td>Yes (every three months until delivery of infant)</td>
<td>No</td>
<td>N/A</td>
<td>NYHA outcome</td>
<td>40 patients (95%) remain in NYHA class I</td>
<td>Yes</td>
</tr>
<tr>
<td>Dabrowski, et al.</td>
<td>Yes (symptoms of heart failure during pregnancy - NYHA class III)</td>
<td>Yes (12-21 years)</td>
<td>No</td>
<td>N/A</td>
<td>Delivery outcome</td>
<td>14 patients delivered 37 (2) wga</td>
<td>N/A</td>
</tr>
</tbody>
</table>

DISCUSSION

The limitation of this study was limited latest studies performed in the last 5 years. It might be due to limited MS cases in developed countries. The best recommendation study for prognostic was cohort; however, we could not find any literature related with this topic.

Mitral stenosis is the most common cause of acquired heart disease during pregnancy. Most of MS cases are caused by rheumatic heart disease. It is poorly tolerated in pregnancy due to the huge change of hemodynamic. The presence of MS in pregnancy with high cardiac output will cause an increase in left atrial and pulmonary pressure resulting in pulmonary oedema. The normal mitral orifice is 4 to 6 cm area by 2D echocardiography short axis. Patient usually complains after the valve area less than 2-2.5 cm with severe MS occurs in valve area less than 1 cm. Around 60% of moderate to severe MR cases will experience episode of pulmonary oedema in 30 weeks of gestational age. This risk will continue during and immediate postpartum period. The physiological of hypercoagulability in pregnancy in relation to increase in left atrial pressure will raise the risk of thrombus formation, atrial fibrillation (AF), and stroke.

Surgical commissurotomy as management of MS during pregnancy was well-known since 1952. Closed or open mitral commissurotomy has shown to be an effective procedure during pregnancy but results in high fetal loss thus, percutaneous mitral balloon commissurotomy was an alternative effective treatment for symptomatic MS. Several studies showed that performing the PMBC had good outcome to pregnant women functional class based on NYHA. Most of them decreased from NYHA III/IV to I/II. It means that there would be a reduction from 6.8% mortality rate in NYHA III/IV to 0.4% in NYHA I/II. ESC guideline for management of pregnant women with MS revealed that percutaneous mitral commissurotomy is preferably performed after 20 weeks’ gestation. It should only be considered in women with NYHA class III/IV and/ or estimated systolic pulmonary artery pressure (PAP) >50mmHg at echocardiography after optimal medical treatment.

For delivery outcome, all studies concluded that more than 80% pregnant women with mitral stenosis undergoing PMBC delivered at term and stated no fetal anomalies found. It was corresponding to other studies where showed...
lower incidence of preterm labor in women after percutaneous mitral commissurotomy (PMCT) before pregnancy compared with non-operated MS however\textsuperscript{13}, there were no significant differences in mode of delivery, mean birth weight or neonatal complications. The radiation is risk is balanced with the improvement of symptoms after procedure. The fluoroscopy operates in the range of 5 rads/minute and less than 20% of doses penetrate to the skin. A study measured that actual dose received by fetus will not more than 0.5 rads therefore, it is no increased risk for congenital malformation.\textsuperscript{14}

Ideally, the procedure should be conducted before becoming pregnant. If MS is diagnosed in early pregnancy, the procedure should be delayed up to 12-14 weeks to minimize radiation exposure during organogenesis. The best interval time to perform is around 26 and 30 weeks to prevent complications such as preterm birth.\textsuperscript{15} Abdominal shielding is recommended during procedure. On mode of delivery, several studies above showed more vaginal delivery than caesarean section. Vaginal delivery can be offered to patients with mild MS or patients with moderate to severe MS in NYHA class I/II without pulmonary hypertension. Meanwhile, ESC guideline suggested caesarean section for patients with moderate to severe MS in NYHA class III/IV or having pulmonary hypertension in spite of medical therapy and PMCT failed to perform.\textsuperscript{12}

**CONCLUSION**

Percutaneous mitral balloon commissurotomy for pregnant women with severe MS is safe during pregnancy; it decreases the NYHA for mother and imposes lower risk for preterm birth and congenital anomaly.

**CONFLICT OF INTEREST**

None declared

**REFERENCES**